These additions to the VOLT portfolio are anatomically designed for two of the most commonly fractured bones Johnson & Johnson MedTech, a global leader in orthopaedic
Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease Johnson
Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptoms
New ultrasound catheter delivers superior image quality, peak maneuverability and seamless CARTO 3 System integration, giving physicians improved visualization for added confidence during cardiac ablation procedures Johnson
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after
Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancer Johnson &
First use in gastric bypass at Memorial Hermann-Texas Medical Center Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, announced completion of the first
Investment builds on almost 140-year legacy of improving and saving lives and supporting American jobs Johnson & Johnson , healthcare’s leading, most comprehensive innovation powerhouse,
Topline results also show investigational targeted oral peptide icotrokinra achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC study Johnson & Johnson
ColorTokens, a global leader in enterprise microsegmentation, announced the appointment of Dr. Guru Gurushankar as Senior Vice President and General Manager for the Healthcare and
Fuel up with free Health Tech Insights
